Head and Neck Cancer Trial, Recruiting NCT05108090 Sponsor: Indiana University Condition: Head and Neck Cancer
Back to Head And Neck Cancer

Head and Neck Cancer Trial, Recruiting

NCT05108090
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 or older at the time of signing the consent form
  • People who are able to give written consent to take part in the study
  • People who have a primary (new) or returning invasive skin cancer called cutaneous squamous cell carcinoma, located on the head or neck, and classified at a certain stage of severity (T2–T4 on the AJCC staging scale) (confirm with trial site)
  • People whose cancer has not spread to nearby lymph nodes or to other parts of the body, based on physical examination and imaging scans
  • People who are medically able to have general anaesthesia for a procedure to check nearby lymph nodes (called a sentinel lymph node biopsy)
  • People who are able to have a CT scan or MRI scan using contrast dye
  • People whose surgery is planned to take place within 8 weeks of their imaging scan

Who may not be able to join:

  • People who show signs that the cancer has spread to nearby skin, lymph nodes, or other parts of the body
  • People who have been diagnosed with another separate squamous cell skin cancer at the same time
  • People who are pregnant
  • People who are not medically able to have general anaesthesia
  • People who are not able to have imaging scans that use contrast dye
  • People who are unable to receive, or who are allergic to, the radioactive substance used during the lymph node procedure (99m-Technetium sulfur colloid)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Jessica Yesensky, MD, Indiana University

Phone: 317-529-6883

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
25 October 2021
Est. completion
1 September 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Incidence of metastasis

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov